Haemacure Corporation Announces Webcast of Presentation at EQUITIES Magazine 56th Anniversary Spring Conference 2007 Investor Meeting

MONTREAL, April 18 /PRNewswire-FirstCall/ - Haemacure Corporation , a specialty biotherapeutics company developing high-value human proteins, today announced the webcast of its presentation at EQUITIES Magazine’s 56th Anniversary Spring Conference 2007 on Friday, April 20, 2007 at The Yale Club in New York, New York, live from 9:30 to 10:00 am, EST.

EQUITIES will webcast the audio portion of the presentation and post the associated slides via its website at www.equitiesmagazine.com. To access the live broadcast via internet in listen-only mode, or the subsequently archived recording, please cut and paste the following link directly into your web browser:

http://www.visualwebcaster.com/event.asp?id=39192

Please visit the site at least five minutes prior to start time for instructions.

About EQUITIES

EQUITIES Magazine (“EQUITIES”), based in Santa Monica, California, is a division of Equities Global Communications, Inc. For 27 years EQUITIES has held investor awareness conferences, bringing together the most active and respected small and mid-cap buy-side investment professionals with small and mid-cap companies. EQUITIES publications have a U.S. readership of approximately 175,000 brokers, hedge funds, chief executive officers, chief financial officers, portfolio managers and retail investors, and more than 37,000 readers of its European version. For further information, visit www.equitiesmagazine.com.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing high-value human therapeutic proteins for commercialization. Haemacure’s research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats.

Hemaseel(TM)HMN, Haemacure’s lead product candidate, is a human-derived fibrin sealant in late-stage clinical development. Haemacure’s second product candidate is human thrombin, a component of its fibrin sealant. Both candidates have applications in the expanding biosurgical market. Follow-on development will focus on surgical hemostats, biomaterial combinations and drug delivery in select therapeutic areas. Haemacure has recently discovered additional specialty proteins in its plasma-derived intermediates and will advance these specialty proteins through partnerships with other pharmaceutical and biotechnology companies.

Forward-looking Statements

Certain statements contained in this news release and oral statements made by representatives of Haemacure that are not historical facts may be considered forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure Corporation does business, stock market volatility, fluctuations in costs, the ability of Haemacure to set up its planned manufacturing facility, the completion and outcome of clinical studies as well as the development of new products, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure Corporation disclaims any intention or obligation to update these statements.

Haemacure Corporation

CONTACT: Gilles Lemieux, Secretary, Haemacure Corporation, (514) 282-3350ext. 22, glemieux@haemacure.com; IR Contact: Dory Valiquette, LaVoie Group,(978) 745-4200 ext. 106, dvaliquette@lavoiegroup.com

MORE ON THIS TOPIC